Core Viewpoint - The company is currently conducting a Phase III clinical trial for its KH110 project, targeting patients aged 50 to 80 with mild to moderate Alzheimer's disease [2] Group 1 - The clinical trial is being carried out at multiple hospitals across the country [2] - The recruitment criteria for the trial specify that participants must be between the ages of 50 and 80 [2] - Information regarding the trial has been registered and made publicly available on the National Medical Products Administration's clinical trial registration platform [2] Group 2 - The company encourages interested individuals or their families to check the registration platform for specific inclusion criteria [2] - Participants are advised to visit nearby research hospitals for evaluation if they wish to join the trial [2]
康弘药业:KH110项目Ⅲ期临床试验正在多家医院开展,招募对象为50~80岁轻、中度阿尔茨海默病患者